Locally advanced or metastatic PD-L1 negative, triple-negative breast cancer research hub

Is datopotamab deruxtecan plus durvalumab more effective than datopotamab deruxtecan alone at treating patients with metastatic breast cancer?

This study looks at a new treatment combination for a specific type of advanced breast cancer. It compares two drugs, datopotamab deruxtecan and durvalumab, given together against datopotamab deruxtecan alone, to see which is more effective and safer for patients with triple-negative breast cancer.